English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

The incidence of dyslipidemia is significantly higher in patients treated with antiretroviral regimens containing ritonavir compared to other regimens not containing ritonavir.1 Moreover, protease inhibitors (PIs) are not equally prone to impair the lipid profile. Regimens with lopinavir/ritonavir (LPV/r) and fosamprenavir/ritonavir (FPV/r) indeed, induce greater elevations in lipid parameters than saquinavir/ritonavir (SQV/r) or atazanavir/ritonavir (ATV/r) or darunavir/ritonavir (DRV/r).2 The objective of this study was to explore the impact on the lipid profile of switching from “older PIs” to DRV/r in virologically suppressed HIV infected patients after 144 weeks of observation. A prospective open label single center study enrolled a total of 13 Caucasian

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy